MARKET

GYRE

GYRE

Gyre Therapeutics Inc
NASDAQ
16.06
-7.34
-31.37%
After Hours: 19.24 +3.18 +19.80% 19:55 12/04 EST
OPEN
24.43
PREV CLOSE
23.40
HIGH
25.84
LOW
16.06
VOLUME
391.02K
TURNOVER
0
52 WEEK HIGH
27.39
52 WEEK LOW
2.831
MARKET CAP
1.23B
P/E (TTM)
-0.7795
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GYRE last week (1127-1201)?
Weekly Report · 23h ago
Catalyst Watch: McDonald's event, Lululemon earnings and GameStop volatility redux
Short interest levels pushed higher on faraday future intelligent electric and fisker. Options trading volume spiked on gamestop ahead of the retailer's earnings report. October factory orders report will be released on december 4. Notable investor events scheduled for next week include mcdonald's event, lululemon earnings.
Seeking Alpha · 3d ago
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Titan machinery shares declined 8.1% to $23.41 on thursday. Minim inc shares jumped 700% after gaining over 13% on wednesday. Salesforce shares gained 8.4% after reporting strong third-quarter results. Redhill biopharma ltd. Shares fell 31% after the company reported weak quarterly results.
Benzinga · 4d ago
Gyre Therapeutics Inc: RW
Press release · 5d ago
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Senestech, inc. Shares declined 50.3% to $0.9189 on tuesday. The company priced a $5.0 million public offering. Icecure medical jumped 90% after the company announced positive results from a study of its prosense technology.
Benzinga · 6d ago
Gyre Therapeutics Inc: Correspondence
Press release · 6d ago
Gyre Therapeutics Inc: [Cover]SEC-generated letter
Press release · 6d ago
Gyre Therapeutics Inc: [Amend]General statement of acquisition of beneficial ownership
Press release · 11/27 23:13
More
About GYRE
Gyre Therapeutics, Inc., formerly Catalyst Biosciences, Inc., is a biotechnology company. The Company is focused on organ fibrosis and inflammatory diseases. The Company is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The Company is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase 3 trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase 1 trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.

Webull offers Gyre Therapeutics Inc stock information, including NASDAQ: GYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GYRE stock methods without spending real money on the virtual paper trading platform.